Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
GLP-1 agonists offer a dual advantage: improving glycaemic control with lower hypoglycaemia risk (when used as monotherapy) and facilitating weight management, both of which may support better long-term outcomes in this vulnerable population
In a separate study involving 190 patients receiving 52 weeks of treatment, remission rates were 36.8%, 45.6%, and 52.0% for the 5, 10, and 15 mg tirzepatide groups, respectively, compared to 18.2% in the placebo group (Loomba et al., 2024)
The statistical significance of the difference between two means assessed twice for the same research group was evaluated using a paired t-test or and Wilcoxon signed-rank test
Sub-therapeutic for both glycemic control and weight
US$ 20.91
US$ 20.55
US$ 20.18
US$ 28.79
US$ 24.50
